Pediatricians recommend new RSV shot for all infants

Pediatricians recommend new RSV shot for all infants

Infants Urged to Receive New Preventive Medication for RSV, Says American Academy of Pediatrics

All infants should receive the new long-acting preventive monoclonal antibody, nirsevimab, for respiratory syncytial virus (RSV), according to the American Academy of Pediatrics (AAP). This recommendation from the nation’s leading pediatrics group aims to ensure equitable access to the medication. RSV is a common, contagious, and sometimes deadly virus, making this preventive treatment crucial for infants.

The AAP’s Urgent Call for Equitable Access

Pediatricians are keenly aware of the dangers posed by RSV and its devastating impact on families. Therefore, the AAP urges federal officials to ensure that nirsevimab is made available and affordable in all communities. The lack of access to this medication for all children is alarming, especially for families living in lower-income and under-resourced communities, as well as infants at the greatest risk for severe RSV illness.

The Power of Monoclonal Antibody Medications

Monoclonal antibody medications such as nirsevimab work by boosting the immune system’s ability to fight off RSV. They have shown promising results in clinical trials, significantly reducing the risk of RSV requiring medical care by 75%.

The U.S. Food and Drug Administration has granted approval to nirsevimab under the brand name Beyfortus. Additionally, the U.S. Centers for Disease Control and Prevention also recommend its use.

Who Should Receive Nirsevimab?

According to the AAP, all infants younger than 8 months, born during or entering their first RSV season, should receive a single dose of nirsevimab. Infants and children aged 8 through 19 months, who are at an increased risk of severe RSV disease and entering their second RSV season, should also receive a single dose.

• Revealing Hidden Consciousness in Comatose Brains
• Pain after heart attack may indicate long-term survival.
• Study finds most healthy infants hospitalized with RSV.

For eligible infants and children who cannot access nirsevimab, they should receive an alternative preventive medication called palivizumab. Palivizumab requires a series of monthly doses and is recommended by the AAP for those at high risk of severe illness.

Ensuring Equitable Access

The AAP emphasizes the need for a comprehensive strategy to ensure equitable access to nirsevimab in hospitals, birthing centers, and other medical practices. They are committed to updating recommendations as needed to address any challenges or new developments in RSV prevention.

RSV Season and Recommendations

RSV season in the United States typically begins in late fall and continues through spring. It is during this time that infants are at a higher risk of contracting the virus. Therefore, it is crucial to provide preventive treatment before the start of the season.

The AAP’s urgent call for equitable access to nirsevimab provides healthcare professionals and families with a proactive approach to safeguarding infants from the potentially severe consequences of RSV.

QUESTION

Newborn babies don’t sleep very much. See Answer

More Information

For more information on RSV, visit the U.S. National Library of Medicine.

SOURCE: American Academy of Pediatrics, news release, Aug. 15, 2023